25 February 2010
Hong Kong and Phoenix – LawFuel.com – DLA Piper today announced that it advised Roth Capital Partners, LLC and Oppenheimer & Co. Inc., full service investment banks, as underwriters and joint book runners in a US$69 million stock offering on the NASDAQ Global Select Market by Yongye International, Inc. (“Yongye”) (NASDAQ: YONG).
Yongye, headquartered in Beijing, is engaged in the development, manufacturing, distribution and sales of fulvic acid based plant and animal nutrient products. The company closed the offering of eight million shares of common stock at a price of $7.50 per share on 22 December 2009 and the underwriters exercised their over-allotment option on 29 December 2009. The offering raised capital for the acquisition of lignite coal resources, construction of a new manufacturing facility and working capital.
Partner Gene Buttrill of DLA Piper Hong Kong led the deal with Associates Tim Sung, Qiu Chen and Fan Fei, all from DLA Piper Hong Kong. Partner Steve Pidgeon spearheaded the team in Phoenix with Associate David Pendergast.
“Yongye’s success is an indication of the recent momentum in public markets around the world. As the global economy rebounds, we have seen strong recovery in offerings from China. As a result, the world’s exchanges are paying increasing attention to how they can attract more Chinese listings like Yongye,” said Gene Butrill, Head of DLA’s Technology Sector in Asia. “Selecting the right listing venue is critical for the growing number of Chinese enterprises, from small to large, seeking an overseas listing. Our global network and local teams are strongly positioned to help clients optimise their listing and expansion plans.”
About Yongye International, Inc.
Yongye International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of Shengmingsu brand plant and animal nutrient products. The Company’s patented and patent pending formulas and proprietary extraction processes allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Inner Mongolia Yongye Nongfeng Biotechnology Co., Ltd., is headquartered in Beijing with administrative and sales offices located in Inner Mongolia, People’s Republic of China. The Company sells its products through distributors located in ten provinces throughout China.